<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02521207</url>
  </required_header>
  <id_info>
    <org_study_id>OXP001-003</org_study_id>
    <nct_id>NCT02521207</nct_id>
  </id_info>
  <brief_title>Pilot Study of OXP001(2) and Brufen in Healthy Subjects</brief_title>
  <official_title>A Two-Part, Randomised, Open-Label, Evaluator-Blinded, Multiple-Dose, Phase I Pilot Study With OXP001 Ibuprofen 400 mg Tablets and Brufen® 400 mg Tablets to Assess the Comparative Bioavailability (Part 1) and Effects on Gastroduodenal Irritation (Part 2) in Healthy Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxford Pharmascience Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oxford Pharmascience Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare the study drug to an already marketed formulation of prescription
      strength ibuprofen (Brufen® the reference product) by looking at how the drug is taken up by
      the body and also by performing a specialist procedure called an endoscopy (or more
      specifically, a gastroscopy). The safety and tolerability of the study drug will also be
      assessed.

      The study will consist of 2 parts involving up to 54 healthy male and female subjects.
      Subjects will be randomly assigned to receive either the study drug or reference product.
      Part 1 will be a cross over study in which up to 10 subjects will receive a single dose of
      800 mg study drug OXP001 or Brufen® on Day 1, then a single dose of 800 mg study drug OXP001
      or Brufen® on Day 4. Part 1 will assess bioavailability and involve an interim decision on
      progression to Part 2. In Part 2, up to 44 subjects will receive a dose of 800 mg OXP001 or
      Brufen® three times daily for 7 days in order to assess pharmacokinetics and stomach
      irritation using endoscopy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Comparison of Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Part 1; Day 1 and Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Comparison of Average Lanza Score</measure>
    <time_frame>Part 2; Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Comparison of Average Number of Erosions</measure>
    <time_frame>Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Comparison of Area Under the Curve (AUC)</measure>
    <time_frame>Part 1; Day 1 and Day 4</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Gastroduodenal Erosions</condition>
  <arm_group>
    <arm_group_label>Part 1 OXP001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OXP001 formulation containing 800mg ibuprofen single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Ibuprofen control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen control 800mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 OXP001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OXP001 formulation containing 800mg ibuprofen three times per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Ibuprofen control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibuprofen control 800mg three times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <arm_group_label>Part 1 OXP001</arm_group_label>
    <arm_group_label>Part 1 Ibuprofen control</arm_group_label>
    <arm_group_label>Part 2 OXP001</arm_group_label>
    <arm_group_label>Part 2 Ibuprofen control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subject

          -  Healthy, normal upper GI tract as indicated by no ulcers or erosions at baseline, as
             assessed by the gastroenterologist conducting the endoscopy (ie Lanza score of 0 in
             both the stomach and duodenum) (Part 2 only)

          -  H. pylori negative

        Exclusion Criteria:

          -  Clinically significant abnormal laboratory parameters

          -  Any clinically significant diseases or conditions affecting the haematopoietic,
             cardiovascular, renal, hepatic, endocrine, pulmonary, central nervous, immunological,
             dermatological, GI or any other body system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Mair</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical Ltd</name>
      <address>
        <city>Nottingham</city>
        <state>Notts</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2015</study_first_submitted>
  <study_first_submitted_qc>August 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>October 27, 2015</last_update_submitted>
  <last_update_submitted_qc>October 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

